MBX Biosciences, Inc. Common Stock
MBX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $19 | $18 | $22 | $15 |
| G&A Expenses | $5 | $4 | $4 | $3 |
| SG&A Expenses | $5 | $4 | $4 | $3 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $24 | $22 | $27 | $19 |
| Operating Income | -$24 | -$22 | -$27 | -$19 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $2 | $2 | $3 | $3 |
| Pre-Tax Income | -$22 | -$19 | -$24 | -$16 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$22 | -$19 | -$24 | -$16 |
| % Margin | – | – | – | – |
| EPS | -0.63 | -0.58 | -0.71 | -0.47 |
| % Growth | -8.6% | 18.3% | -51.1% | – |
| EPS Diluted | -0.63 | -0.58 | -0.71 | -0.47 |
| Weighted Avg Shares Out | 34 | 33 | 33 | 33 |
| Weighted Avg Shares Out Dil | 34 | 33 | 33 | 33 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $2 | $3 | $3 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$22 | -$22 | -$26 | -$19 |
| % Margin | – | – | – | – |